Key Summary
- Nasal spray EURneffy can be used during the emergency treatment for anaphylaxis, a serious allergic reaction
- Anaphylaxis is a sudden, severe, and sometimes life-threatening allergic reaction that causes a drop in blood pressure and breathing difficulties
- EURneffy will be available across the UK in a ready-to-use single-dose nasal spray form
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a nasal spray, the first needle-free emergency treatment for anaphylaxis, a serious allergic reaction that could sometimes be life-threatening.
The MHRA on Friday (18) 2025, approved adrenaline (epinephrine) nasal spray (EURneffy), and it can be used for treating adults and children who weigh 30 kg (about 66 pounds) or more.
Anaphylaxis is a sudden, severe and sometimes life-threatening allergic reaction that causes a drop in blood pressure and breathing difficulties.
Adrenaline has been a well-established treatment for anaphylaxis and is administered through auto-injectors.
It will now also be available in a ready-to-use single-dose nasal spray form that delivers its entire contents (2mg) upon activation.
Users should not press the plunger before inserting the product into the nostril, or it may be lost.
Adrenaline (epinephrine) nasal spray can also be used when the nose is congested due to a cold or allergy.
Patients have been advised to carry two nasal sprays with them in case a second dose is needed, and let friends or family know they have them in case of an emergency.
